SYRE vs BIIB: Which Stock is Better?
Side-by-side comparison of Spyre Therapeutics Inc and Biogen Inc in 2026
SYRE
Spyre Therapeutics Inc
$69.70
BIIB
Biogen Inc
$177.35
Key Metrics Comparison
| Metric | SYRE | BIIB | Winner |
|---|---|---|---|
| Market Cap | $5.44B | $26.03B | BIIB |
| P/E Ratio | N/A | 20.04 | BIIB |
| EPS (TTM) | $N/A | $8.85 | BIIB |
| Revenue Growth | 0.0% | -0.1% | BIIB |
| Gross Margin | 0.0% | 78.9% | BIIB |
Analyze SYRE
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is SYRE or BIIB a better investment?
Comparing SYRE and BIIB: Spyre Therapeutics Inc has a market cap of $5.44B while Biogen Inc has $26.03B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between SYRE and BIIB?
SYRE (Spyre Therapeutics Inc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: SYRE or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: SYRE or BIIB?
SYRE has higher revenue growth at 0.0% vs -0.1% for BIIB.
Which company is more profitable: SYRE or BIIB?
Biogen Inc (BIIB) has higher gross margins at 78.9% compared to 0.0% for SYRE.
Which is the larger company: SYRE or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $26.03B compared to $5.44B for SYRE.
Should I buy SYRE or BIIB in 2026?
Both SYRE and BIIB have investment merit. SYRE trades at $69.70 while BIIB trades at $177.35. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between SYRE and BIIB stock?
Key differences: Market Cap ($5.44B vs $26.03B), P/E Ratio (N/A vs 20.0x), Revenue Growth (0.0% vs -0.1%), Gross Margin (0.0% vs 78.9%).